These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 27752360)
1. Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. Cappelli LC; Shah AA; Bingham CO RMD Open; 2016; 2(2):e000321. PubMed ID: 27752360 [TBL] [Abstract][Full Text] [Related]
2. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Cappelli LC; Shah AA; Bingham CO Rheum Dis Clin North Am; 2017 Feb; 43(1):65-78. PubMed ID: 27890174 [TBL] [Abstract][Full Text] [Related]
3. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Cappelli LC; Gutierrez AK; Bingham CO; Shah AA Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041 [TBL] [Abstract][Full Text] [Related]
4. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Cappelli LC; Gutierrez AK; Baer AN; Albayda J; Manno RL; Haque U; Lipson EJ; Bleich KB; Shah AA; Naidoo J; Brahmer JR; Le D; Bingham CO Ann Rheum Dis; 2017 Jan; 76(1):43-50. PubMed ID: 27307501 [TBL] [Abstract][Full Text] [Related]
5. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Ohnuma K; Hatano R; Dang NH; Morimoto C Mod Rheumatol; 2019 Sep; 29(5):721-732. PubMed ID: 30285531 [TBL] [Abstract][Full Text] [Related]
6. Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy. Shen P; Deng X; Hu Z; Chen Z; Huang Y; Wang K; Qin K; Huang Y; Ba X; Yan J; Han L; Tu S Front Med (Lausanne); 2021; 8():762247. PubMed ID: 34805229 [TBL] [Abstract][Full Text] [Related]
7. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Cappelli LC; Brahmer JR; Forde PM; Le DT; Lipson EJ; Naidoo J; Zheng L; Bingham CO; Shah AA Semin Arthritis Rheum; 2018 Dec; 48(3):553-557. PubMed ID: 29573850 [TBL] [Abstract][Full Text] [Related]
8. Treatment of rheumatic adverse events of cancer immunotherapy. Reid P; Cappelli LC Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101805. PubMed ID: 36539321 [TBL] [Abstract][Full Text] [Related]
9. Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. Calabrese C; Kirchner E; Kontzias A; Velcheti V; Calabrese LH RMD Open; 2017; 3(1):e000412. PubMed ID: 28405474 [TBL] [Abstract][Full Text] [Related]
10. [Autoimmune reactions to immune checkpoint inhibitors]. Pönisch W; Alten R; Baerwald C Z Rheumatol; 2017 Oct; 76(Suppl 2):57-62. PubMed ID: 29330759 [TBL] [Abstract][Full Text] [Related]
11. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. Jamal S; Hudson M; Fifi-Mah A; Ye C J Rheumatol; 2020 Feb; 47(2):166-175. PubMed ID: 31308203 [TBL] [Abstract][Full Text] [Related]
12. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors-A 2023 Update. Dang QM; Watanabe R; Shiomi M; Fukumoto K; Nobashi TW; Okano T; Yamada S; Hashimoto M Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982715 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772 [TBL] [Abstract][Full Text] [Related]
14. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042 [TBL] [Abstract][Full Text] [Related]
15. Musculoskeletal adverse reactions after immunotherapy for cancer: A case series. Creţu I; Bojincă M; Milicescu M; Cursaru A; Șerban B; Crețu B; Iordache S; Pop CS; Cîrstoiu C; Ionescu R Exp Ther Med; 2021 Sep; 22(3):1027. PubMed ID: 34373713 [TBL] [Abstract][Full Text] [Related]
16. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Tocut M; Brenner R; Zandman-Goddard G Autoimmun Rev; 2018 Jun; 17(6):610-616. PubMed ID: 29631064 [TBL] [Abstract][Full Text] [Related]
17. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors. Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738 [TBL] [Abstract][Full Text] [Related]
18. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Abdel-Wahab N; Suarez-Almazor ME Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084 [TBL] [Abstract][Full Text] [Related]
19. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors. Xiao Y; Zeng L; Shen Q; Zhou Z; Mao Z; Wang Q; Zhang X; Li Y; Yao W J Immunol Res; 2020; 2020():2640273. PubMed ID: 32832568 [TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know? Gediz F; Kobak S Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]